DSwiss Inc. reported a revenue of $2.92 million for the fiscal year ending December 31, 2025, marking a 6.16% decrease from the previous year's revenue of $3.11 million. The decline in revenue is attributed primarily to a reduction in OEM/ODM sales of nutraceutical and skincare products. The company's cost of revenue also decreased to $2.36 million from $2.49 million in 2024, resulting in a gross profit of $564,562, down from $623,271 the previous year. Consequently, the gross margin fell to 19.33% from 20.02%, reflecting the challenges faced in maintaining profitability amid declining sales.
In terms of operational changes, DSwiss made a significant strategic move by acquiring the remaining 60% equity interest in DSwiss Biotech Sdn Bhd, making it a wholly-owned subsidiary. This acquisition, completed on January 18, 2023, for a nominal consideration of RM1, is expected to enhance the company's research and development capabilities. The company has also expanded its workforce, increasing its employee count to 30 full-time staff members, which includes key hires in R&D and operations to support its growth initiatives.
The company has been actively pursuing geographic expansion, focusing on strengthening its presence in the Asia-Pacific region while exploring new markets, including the United States and China. DSwiss has reported a growing customer base, driven by enhanced marketing efforts, particularly through social media channels. The company aims to increase its social media engagement by 100% by the end of 2026, reflecting its commitment to leveraging digital platforms for brand visibility and customer interaction.
Despite the challenges faced in 2025, DSwiss remains optimistic about its future growth prospects. The company plans to invest in talent development and strategic partnerships to bolster its market position. Additionally, DSwiss is exploring opportunities for mergers and acquisitions to enhance its operational capabilities and expand its product offerings. The management has indicated that while current revenues are sufficient to fund operations, they may seek additional capital to support future growth and expansion plans.
Overall, DSwiss Inc. is navigating a challenging market environment while positioning itself for future growth through strategic acquisitions, workforce expansion, and enhanced marketing efforts. The company’s focus on innovation and quality in its product offerings remains central to its strategy as it aims to solidify its presence in the health and beauty sectors.
About DSwiss Inc
DSwiss, Inc. is a biotech nutraceutical company specializing in high-quality health, skincare, and personal care products. It offers OEM/ODM manufacturing, functional foods, supplements, and natural remedies, serving markets across Asia and globally. Focused on innovation, quality, and regulatory compliance, it leverages advanced R&D, strategic partnerships, and digital marketing to deliver customized solutions and expand its global presence in health and beauty industries.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.